compass Archives | Psychedelic Spotlight

Psilocybin showed rapid antidepressant effects for most patients, but only 1 in 5 participants showed significant improvement at 12 weeks

What investors need to know about the intellectual property behind medicine’s next big growth area

Math over Myth is your weekly update on psychedelic stocks and ETFs, including ATAI, COMPASS, Cybin, GH Research, Mindset, Numinus, and more

Track the monthly performance of the psychedelic stock sector with our Math over Myth Stock News Roundup

If you want to invest in psychedelic stocks, ignore the hype and look at the technicals. We take a deep dive on atai Life Sciences & COMPASS Pathways

Compass Pathways faces a legal challenge from Terran Biosciences over the potential theft of intellectual property

Psychedelic companies rely on novel patents to boost their value, but many players in the space are chasing the same IP

This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.

Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.